I refer to the article "Vi conjugate Typhoid Vaccine" written by Garg
SP(1) on behalf of the manufacturer of Peda TyphTM
in response to my previous article on the same subject(2). The author
states that "this novel vaccine has been found to be safe and effective
in inducing very high levels of immune response (>90%) in infants, young
children and adults", and goes further to claim that "this new
vaccine can be used to vaccinate and protect patients after clinical
recovery and thus prevent disease carriers and relapses"(1). Both
these statements are misleading as for any typhoid vaccine, immuogenicity
is not equal to efficacy, and serological correlates of protection for
typhoid vaccines are not known. If the correlates were well established
(as quoted by the author citing an old 1935 reference) why were the
efficacy trials conducted for all the typhoid vaccines subsequently before
they were marketed. Such field efficacy trials were also conducted for the
experimental Vi conjugate vaccine (Vi-rEPA) by Dr. Robbins and are
underway for other Vi conjugate vaccines in India. No such efficacy trial
is available for Peda TyphTM anywhere in India or
world. Claims that the vaccine will work in preventing carrier stage, and
that it is expected to result in eradication of typhoid fever, are tall
and misleading as no such data exists for any of the typhoid vaccine.
Author further states that "over the years, the
protective immunity conferred by Vi antigen has been well established and
adopted by the WHO" and quote a 1994 WHO Technical Report Series for
the same(1). Again, this is misleading as the said reference does not talk
of any such correlate and the said document anyway applies to Vi
polysaccharide (unconjugated) vaccine and not Vi conjugate vaccine (which
is a totally different vaccine). As the current Indian vaccine Peda TyphTM
is different from the experimental Vi conjugate vaccine (Vi-rEPA) of Dr
Robbin’s, the field efficacy data of later can not be extrapolated or
bridged to former.
Lastly, when I suggested conducting a proper field
efficacy trial enrolling enough number of subjects, it meant a field
efficacy trial in a randomized double blind placebo controlled fashion,
and not in a haphazard manner. The onus of conducting a scientific and
authentic field efficacy trial lies on the manufacturer (that too before
marketing), and not doctors, the end users. I reiterate that there is not
enough evidence in using the so called first Indian Vi conjugate vaccine.
References
1. Garg SP. Vi conjugate typhoid vaccine. Indian
Pediatr 2009; 46: 736-737.
2. Shah N. Indian conjugate typhoid vaccine: Do we have
enough evidence. Indian Pediatr 2009; 46: 181-182.
Editorial Note: The present communication is the
last in the series of letters on the Vi conjugte typhoid vaccine, which
started from Februry 2009 issue of Indian Pediatrics.